今泉 和良

Medicine & Life Sciences

1. Lung Neoplasms 100%
2. Lung 93%
3. Non-Small Cell Lung Carcinoma 77%
4. Interstitial Lung Diseases 37%
5. Neoplasms 36%
6. Gefitinib 32%
7. Bronchoscopy 31%
8. Biopsy 30%
9. Carcinoma 28%
10. Carboplatin 28%
11. Transforming Growth Factors 26%
12. Tomography 25%
13. Epithelial-Mesenchymal Transition 23%
14. ErbB Receptors 23%
15. Chemokine CCL22 23%
16. Idiopathic Pulmonary Fibrosis 23%
17. Induced Pluripotent Stem Cells 22%
18. Pneumonia 21%
19. Anions 21%
20. Mutation 21%
21. Asthma 20%
22. Therapeutics 20%
23. Pemetrexed 19%
24. CD40 Ligand 19%
25. Pulmonary Fibrosis 19%
26. Fibroblasts 19%
27. Cisplatin 18%
28. Chemokines 18%
29. Interferons 17%
30. Heme Oxygenase-1 17%
31. Bronchi 17%
32. Epithelial Cells 16%
33. Pleural Effusion 16%
34. Quinolones 16%
35. Dyspnea 15%
36. Chronic Obstructive Pulmonary Disease 15%
37. Respiratory Tract Infections 15%
38. Safety 15%
39. Needles 15%
40. Malignant Pleural Effusion 14%
41. Thorax 14%
42. Gatifloxacin 14%
43. Erlotinib Hydrochloride 14%
44. Pharmaceutical Preparations 13%
45. Immunity 13%
46. Bronchiolitis Obliterans 13%
47. Phenotype 13%
48. Protein-Tyrosine Kinases 13%
49. Up-Regulation 13%
50. Acute Lung Injury 12%